With the use of more intensive antiretroviral therapies (highly-active antiretroviral therapy, HAART) particularly in first world countries, reductions in the mortality and morbidity of HIV infection are being seen. However, though the prevalence of symptoms may change, symptom control does continue to be a problem for many people with HIV, particularly as their disease progresses. This is the second of 2 CME articles about palliative care and HIV infection. The first gave a background to palliative care, and covered symptom control of pain1. This article gives suggestions for the treatment of common gastrointestinal symptoms in HIV infection; nausea and vomiting, cachexia and anorexia and chronic diarrhoea.
Get full access to this article
View all access options for this article.
References
1.
MeyerM.. Palliative care and AIDS: 1 —Pain.Int J STD AIDS1999; 10: 80–8.
2.
SimsR., MossV.. Palliative Care for People with AIDS.London: Edward Arnold, 1995
3.
LichterI.. Palliation of nausea and vomiting.Prog Palliative Care1994; 2: 177–81.
4.
BainesM.J.. Nausea, vomiting and intestinal obstruction—ABC of palliative care.BMJ1997; 315: 8,1149–50
5.
MannixK.A.. Palliation of nausea and vomiting. In: DoyleD.. Oxford Textbook of Palliative Medicine, 2nd edn.Oxford University Press, 1998: 489–99
6.
TwycrossR., BackI.. Nausea and vomiting in advanced cancer.Eur J Palliative Care1998; 5: 39–45.
7.
TwycrossR.. Palliative Care Formulary 1.Oxford: Oxford University Press, 1998
8.
British National Formulary Number 36, September 1998. British Medical Association and Royal Pharmaceutical Society of Great Britain, 1998
9.
TrevinoS.. Tropisetron efficacy and tolerability in the AIDS nausea and vomiting treatment, Int Conf AIDS1996; 11: 297
10.
BalanoK.B.. Ondansetron use for intractable nausea and vomiting in AIDS patients, Int Conf AIDS1996; 11: 108
11.
GreenblattD.J.. Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular and oral lorazepam.J Pharm Sci1982; 71: 248–52.
12.
TwycrossR.. The risks and benefits of corticosteroids in advanced cancer.Drug Safety1994; 11: 163–78.
13.
Focus on Corticosteroids Current Problems in Pharmacovigilance.Committee on Safety of Medicines and Medicines Control Agency1998; 24: 5–10.
14.
BrueraE.. Anorexia, cachexia, and nutrition — ABC of palliative care.BMJ1997; 315: 1219–22.
15.
GorterR.. Management of anorexia-cachexia associated with cancer and HIV infection.Oncology1991; 5(suppl): 13–17
16.
MacallanD.C.. Energy expenditure and wasting in human immunodeficiency virus infection.N Engl J Med1995; 333: 83–8.
17.
TchekmedyianN.S.. Costs and benefits of nutrition support in cancer.Oncology1995; 9(suppl): 79–84
18.
BealJ.E.. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia.J Pain Symptom Manage1997; 14: 7–14.
19.
KottlerD.P.. Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS.Am J Clin Nut1989; 50: 444–7.
20.
JaskowiakN.T., AlexanderH.R.. The pathophysiology of cancer cachexia. In: DoyleD.. Oxford Textbook of Palliative Medicine, 2nd edn.Oxford: Oxford University Press, 1998: 534–48
21.
KotlerD.P.. Wasting syndrome: nutritional support in HIV infection.AIDS Res Hum Retroviruses1994; 10: 931–4.
22.
MaltoniM.. Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients.Support Care Cancer1997; 5: 130–5.
23.
BrueraE., FainsingerR.L.. Clinical management of cachexia and anorexia. In: DoyleD.., Oxford Textbook of Palliative Medicine, 2nd edn.Oxford: Oxford University Press, 1998: 548–57
24.
SchwenkA.. Enteral nutrition in AIDS cachexia: controlled study on the role of fiber.Int Conf AIDS1996; 11: 102
25.
FainsingerR.L.. The modern management of cancer related cachexia in palliative care.Prog Palliative Care1997; 5: 191–5.
26.
BrueraE.. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study.Cancer Treat Rep1985; 69: 751–4.
27.
MoertelC.G.. Corticosteroid therapy of preterminal gastrointestinal cancer.Cancer1974; 33: 1607–9.
28.
LoprenziC.L.. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia.J National Cancer Inst1990; 82: 1127–32.
29.
Von RoennJ.H.. Megestrol acetate in patients with AIDS-related cachexia.Ann Intern Med1994; 121: 393–9.
30.
OsterM.H.. Megestrol acetate in patients with AIDS and cachexia.Ann Intern Med1994; 121: 400–8.
31.
BellerE.. Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: a randomised placebo-controlled trial.Ann Oncol1997; 8: 277–83.
32.
BealJ.E.. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS.J Pain Symptom Manage1995; 10: 89–97.
33.
SykesN.P.. Constipation and diarrhoea. In: DoyleD.. Oxford Textbook of Palliative Medicine, 2nd edn.Oxford: Oxford University Press, 1998: 513–26
CelloJ.P.. Gastrointestinal tract manifestations of AIDS. In: SandeM.A., VolberdingP.A., eds. The Medical Management of AIDS.WB Saunders1996: 185–95
36.
UipD.E.. Roxithromycin treatment for diarrhoea caused by Cryptosporidium spp. in patients with AIDS.J Antimicrobial Chemotherapy1998; 41(suppl. B): 93–7
37.
SprinzE.. AIDS-related cryptosporidial diarrhoea: an open study with roxithromycin.J Antimicrobial Chemotherapy1998; 41(suppl. B): 85–91
38.
KingE.. Dealing with side effects: why many treatments have unwanted effects and how to minimise them.AIDS Treatment Update1996; 41: 1–3 & table
39.
KelleherP.. HIV infection: the spectrum of symptoms and disease in male and female patients attending a London hospice.Palliative Med1997; 11: 152–8.
40.
BlanshardC., FrancisN., GlazzardB.G.. Investigation of chronic diarrhoea in acquired immunodeficiency syndrome. A prospective study of 155 patients.Gut1996; 39: 824–32.
41.
MorrowR.J.. Diarrhoea and its treatment.Iowa Pharmacist October 1976; 5/26
42.
SimonD.M.. Multicentre trial of octreotide in patients with refractory acquired immunodeficiency syndrome-associated diarrhea.Gastroenterology1995; 108: 1753–60.
